Brought to you by 
Orphan Medical licenses Xyrem rights to Celltech
22 May 2015
Executive Summary
Orphan Medical (drugs for rare diseases) has licensed Celltech Pharmaceuticals European marketing rights to Xyrem (sodium oxybate), a treatment for cataplexy associated with narcolepsy. The deal will last 10 years from European approval and will be automatically extended if the licensee wishes.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Intra-Biotech Deal
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Orphan Medical licenses Xyrem rights to Celltech
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice